Vyleesi Cost in Alaska 2026: Prices, Insurance, and Compounded Options

What Does Vyleesi Cost in Alaska in 2026?

Brand-name Vyleesi lists at $1,200 per month in Alaska, matching the national wholesale acquisition cost set by Palatin Technologies. Cash-pay patients at Alaska retail pharmacies pay the same $1,200 without insurance negotiation. Compounded bremelanotide from a state-licensed 503A pharmacy costs approximately $140 per month, making it the lowest-cost legal pathway for most Alaskan patients.

The $1,200 WAC figure comes directly from Palatin Technologies' published pricing and is consistent with what GoodRx and major pharmacy benefit managers report for the 2026 benefit year. No significant regional discount exists for Alaska residents purchasing the brand product without insurance, because Vyleesi is not subject to the Medicaid best-price discount that sometimes reduces costs in other states. The FDA approved bremelanotide on June 21, 2019, for hypoactive sexual desire disorder (HSDD) in premenopausal women, as documented in the agency's drug approval package (FDA NDA 210557).

HSDD is defined by the Diagnostic and Statistical Manual of Mental Disorders (DSM-5) as persistently deficient sexual desire causing marked distress. Bremelanotide works by activating melanocortin receptors (MC1R, MC3R, MC4R) in the central nervous system rather than acting peripherally, a mechanism distinct from flibanserin (PMID 26919740). That central mechanism is why the drug requires subcutaneous injection rather than oral dosing, and why nausea (affecting roughly 40% of patients in clinical trials) is the most common adverse effect (PMID 31060191).

For Alaskan patients paying cash, the realistic choices in 2026 are: brand Vyleesi at $1,200, compounded bremelanotide at around $140, or flibanserin (Addyi) as an oral alternative with its own cost profile.

Does Alaska Medicaid Cover Vyleesi?

Alaska Medicaid does not cover Vyleesi as of 2026. The Alaska Division of Health Care Services excludes bremelanotide from its preferred drug list, meaning Medicaid enrollees receive no reimbursement even with a prior authorization request.

This exclusion is not unique to Alaska. Most state Medicaid programs have declined to add bremelanotide to their formularies since approval, citing cost-effectiveness data and the drug's "as-needed" rather than daily dosing schedule. The Institute for Clinical and Economic Review (ICER) published an evidence report in 2019 concluding that bremelanotide's cost-effectiveness ratio exceeded $500,000 per quality-adjusted life-year at the then-current list price, which influenced multiple state formulary decisions (ICER 2019 HSDD Report). Alaska Medicaid generally follows the Medicaid Drug Rebate Program rules under 42 U.S.C. § 1396r-8, but formulary inclusion remains a state discretionary choice for non-preferred drugs.

Patients on Alaska Medicaid who have a documented HSDD diagnosis should ask their prescriber about flibanserin 100 mg (Addyi), which carries a different formulary profile in some plans, or about non-pharmacologic options including cognitive behavioral therapy and sex therapy, both of which have evidence support from the American College of Obstetricians and Gynecologists (ACOG Practice Bulletin).

Dual-eligible patients (Medicare and Medicaid) face the same gap: Medicare Part D does not cover drugs approved solely for sexual dysfunction under the statutory exclusion at 42 U.S.C. § 1395w-102(e)(2).

Is Compounded Bremelanotide Legal in Alaska?

Compounded bremelanotide is legal in Alaska when prepared by a pharmacy operating under section 503A of the Federal Food, Drug, and Cosmetic Act. At roughly $140 per month, it costs about 88% less than brand Vyleesi. The key legal requirement is that the compounding pharmacy hold a valid state pharmacy license and compound only on receipt of a valid patient-specific prescription.

Section 503A governs traditional compounding pharmacies that prepare drugs for individual patients based on a prescription. Bremelanotide's active pharmaceutical ingredient (API) is not on the FDA's list of bulk drug substances that may not be used in compounding under 503A, so compounding from bulk API is currently permissible for licensed 503A pharmacies (FDA 503A Bulks List). This distinguishes bremelanotide from semaglutide and tirzepatide, which faced FDA enforcement actions during the GLP-1 shortage period.

Alaska's pharmacy licensing authority, the Alaska Board of Pharmacy, requires that any out-of-state 503A pharmacy shipping into Alaska hold a nonresident pharmacy permit from the state. Patients should verify this permit before ordering. A licensed compounding pharmacy will provide a certificate of analysis for each batch, documenting peptide purity, sterility testing, and endotoxin levels. Patients should request these documents before use.

Bremelanotide's compounded form is typically supplied as a lyophilized powder for reconstitution, dosed at 1.75 mg per injection, matching the FDA-approved dose studied in the RECONNECT trials (PMID 31060191). Some compounders offer alternative concentrations; patients should confirm their prescriber has specified 1.75 mg per dose to match the evidence base.

The American Society of Health-System Pharmacists (ASHP) guidance on sterile compounding, published in the American Journal of Health-System Pharmacy, recommends patients using compounded injectables at home receive training on aseptic technique and sharps disposal (PMID 29378822). Alaska's sharps disposal rules allow patients to use household sharps containers placed in a sealed puncture-resistant container before trash disposal.

What Does the Clinical Evidence Say About Bremelanotide?

The RECONNECT program, published in Obstetrics and Gynecology in 2019, comprised two phase 3 randomized controlled trials totaling approximately 1,267 premenopausal women with HSDD. In the pooled analysis, bremelanotide 1.75 mg produced a statistically significant increase in satisfying sexual events and a reduction in distress scores versus placebo (P<0.001 for the co-primary endpoints) (PMID 31060191). The number needed to treat to produce a clinically meaningful improvement in desire score was approximately 8, based on the reported responder rates of 25% for bremelanotide versus 17% for placebo.

Nausea occurred in 40.1% of bremelanotide-treated patients versus 1.2% on placebo, and flushing occurred in 20.2% versus 0.4%. Nausea typically resolved within 12 hours. Bremelanotide produces a transient mean increase in systolic blood pressure of approximately 2 mmHg and diastolic blood pressure of approximately 1 mmHg at 4 hours post-dose; the FDA label therefore recommends against use in patients with known cardiovascular disease or uncontrolled hypertension (FDA prescribing information).

A 52-week open-label safety extension study, also published in the context of the RECONNECT program, confirmed no new safety signals with extended use. Focal hyperpigmentation (darkening of the face, gums, and breasts) was reported in 1% of patients and may not fully resolve after stopping treatment (PMID 31060191).

The International Society for the Study of Women's Sexual Health (ISSWSH) 2022 clinical practice guidelines list bremelanotide as a first-line pharmacologic option for premenopausal women with HSDD, alongside flibanserin, when the etiology is not attributable to a reversible cause such as a medication side effect (ISSWSH Process of Care, PMID 35036967).

Which Insurance Plans Cover Vyleesi in Alaska?

Commercial insurance coverage for Vyleesi in Alaska varies by plan, and no statewide mandate requires coverage. Most large commercial plans either exclude the drug entirely or place it on a specialty tier requiring prior authorization.

The most reliable coverage pathway for commercially insured Alaskans is through employer-sponsored plans that include specialty drug benefits and have added bremelanotide to their formulary under the women's health benefit. Premera Blue Cross, the dominant commercial insurer in Alaska, has historically required prior authorization documenting HSDD diagnosis, failure of at least one non-pharmacologic treatment, and premenopausal status. Coverage decisions change annually with formulary updates; patients should confirm the current-year formulary with their plan's member services line.

Federal employee health plans under FEHB vary by carrier. Some FEHB options, including certain BlueCross BlueShield Association plans, cover Vyleesi at the specialty tier with a prior authorization requirement. Alaska state employees covered under the Alaska Public Employees' Retirement System (PERS) health trust should consult their Summary Plan Description for current formulary status.

For patients with commercial coverage who face a high copay, the Palatin Technologies Vyleesi savings card can reduce out-of-pocket cost to $0 per month for eligible patients. Eligibility excludes federal and state government insurance programs (Medicaid, Medicare, TRICARE, VA, FEHB), which is a standard restriction for manufacturer copay assistance programs under the federal anti-kickback safe harbor rules (OIG Advisory Opinion guidance at HHS.gov).

Patients denied coverage should request a step-therapy exception in writing, referencing the ISSWSH 2022 guidelines, which state: "For women with HSDD, pharmacotherapy with bremelanotide or flibanserin should be offered when distress is present and reversible causes have been addressed" (PMID 35036967). A physician-authored letter of medical necessity citing this guideline language and the patient's documented symptom distress score can support the appeal.

How Does the Palatin Technologies Savings Card Work in Alaska?

The Palatin savings card reduces brand Vyleesi cost to $0 per fill for eligible commercially insured patients and to a reduced cash price for uninsured patients. Alaska residents can enroll at the Vyleesi manufacturer website or through a participating pharmacy.

The card functions as a secondary payer. The patient's commercial insurance pays its contracted rate first, and the savings card covers the patient's remaining cost up to the program's monthly cap. For uninsured patients, the program offers a cash-pay discount that may reduce the $1,200 list price, though the exact discount amount varies and is confirmed at the pharmacy counter. The program explicitly excludes Alaska Medicaid, Medicare Part D, TRICARE, and VA beneficiaries.

Enrollment requires a valid prescription, the patient's date of birth, and confirmation that the patient is a U.S. resident. There is no income threshold for the commercial copay elimination benefit. The savings card may be used a maximum of 12 times per calendar year, corresponding to 12 monthly fills. Patients in remote Alaskan communities can use the card at mail-order pharmacies.

One practical limitation: very few Alaska retail pharmacies stock Vyleesi as a shelf item given its limited market volume. Most dispensing occurs through specialty pharmacy networks or mail order. Patients should confirm with their prescriber which specialty pharmacy is in-network for their plan (FDA drug database for dispensing information).

Telehealth Access to Vyleesi Prescriptions in Alaska

Telehealth prescribing of bremelanotide is legal in Alaska under the state's telehealth framework. Alaska Statute 08.64.364 permits prescribing via synchronous audio-video telehealth after an appropriate clinical evaluation, which for HSDD means documenting desire distress using a validated instrument such as the Female Sexual Distress Scale-Revised (FSDS-R) or the Female Sexual Function Index (FSFI).

Alaska has no telemedicine-specific restrictions that would prevent an out-of-state licensed physician from prescribing to an Alaskan patient, provided the physician holds an Alaska medical license or qualifies under a recognized interstate compact. The Interstate Medical Licensure Compact (IMLC) currently includes Alaska as a member state, allowing eligible physicians licensed in compact states to obtain an Alaska license more quickly (IMLC member state list). This matters for rural Alaskan patients who may have no nearby gynecologist or sexual medicine specialist.

A telehealth HSDD evaluation typically includes a review of the patient's medical history, current medications (particularly SSRIs, OCPs, and antipsychotics, which can suppress desire), hormonal status, and relationship context. The ISSWSH process-of-care model, published in the Journal of Sexual Medicine, recommends screening for depression, anxiety, and partner sexual dysfunction before initiating pharmacotherapy (PMID 35036967). A telehealth provider skipping these steps is not following standard of care.

Patients who receive a bremelanotide prescription via telehealth can have it sent directly to a mail-order specialty pharmacy. Compounded bremelanotide prescriptions from telehealth providers to 503A pharmacies follow the same legal pathway, provided the pharmacy holds an Alaska nonresident pharmacy permit. The compounded product is then shipped cold-chain to the patient's address, including addresses in rural Alaska served by USPS.

Cost Comparison: Brand Vyleesi vs. Compounded Bremelanotide vs. Flibanserin in Alaska

Choosing between brand, compounded, and alternative agents involves price, evidence grade, and logistics. Here is a direct comparison for Alaskan patients in 2026.

Brand Vyleesi at $1,200/month offers the FDA-approved formulation with full manufacturer quality control, access to the Palatin savings card (bringing cost to $0 for eligible commercial insurance patients), and specialty pharmacy support. Every lot is tested under FDA manufacturing standards (21 CFR Part 211). The auto-injector device is ready to use without reconstitution.

Compounded bremelanotide at roughly $140/month is the same active molecule at the same 1.75 mg dose, but manufactured under 503A compounding standards rather than FDA-approved GMP. The evidence base, the RECONNECT trials, was built using the brand formulation. Compounded products lack the manufacturer savings card. Patients typically receive a lyophilized vial requiring reconstitution with bacteriostatic water, which adds a preparation step.

Flibanserin 100 mg (Addyi) is an oral daily tablet, FDA-approved for premenopausal HSDD since 2015 (FDA NDA 022526). Its cash price in Alaska is approximately $800 to $900 per month without insurance. It carries a REMS program requirement due to hypotension risk with alcohol. Generic flibanserin became available in 2022 and costs closer to $200 to $400 per month at compounding-adjacent generic pharmacies, though availability in Alaska may be limited. A head-to-head comparison published in the Journal of Sexual Medicine found similar effect sizes for bremelanotide and flibanserin on the FSFI desire domain, though the trials differed in design (PMID 30521143).

For an uninsured Alaskan patient without access to the Palatin savings card, compounded bremelanotide at $140/month or generic flibanserin (where available) at $200 to $400/month are the most accessible pharmacologic options. For a commercially insured patient with a plan that covers Vyleesi, the savings card can eliminate out-of-pocket cost entirely.

Practical Steps for Alaska Patients in 2026

Getting bremelanotide in Alaska requires navigating pharmacy networks, insurance rules, and telehealth options. The following steps reflect standard clinical and administrative practice.

First, confirm the HSDD diagnosis with a licensed provider. A score of 11 or higher on the FSDS-R (distress subscale) is the validated threshold used in the RECONNECT trials and in ISSWSH guidelines to define clinically significant distress (PMID 31060191). Second, have the prescriber check current Alaska Medicaid formulary status if applicable, and request a prior authorization for commercial plans. Third, if insurance is denied, evaluate whether the Palatin savings card covers remaining cost.

If brand cost remains prohibitive after the savings card, request a prescription explicitly written for "bremelanotide 1.75 mg subcutaneous injection" without brand specification. That wording allows dispensing at a licensed 503A compounding pharmacy. Confirm the compounding pharmacy holds an Alaska nonresident pharmacy permit by checking the Alaska Board of Pharmacy license lookup tool at the Division of Corporations, Business, and Professional Licensing website (Alaska CBPL).

Request a certificate of analysis for the specific compounded lot before first use. The COA should document: peptide identity by HPLC, purity of at least 98%, sterility confirmation per USP 71, and endotoxin testing per USP 85. Any reputable 503A pharmacy will provide this on request (USP standards for sterile compounding).

Administer bremelanotide 45 minutes before anticipated sexual activity, in the abdomen or thigh, rotating injection sites. Do not use more than one dose within 24 hours. Monitor blood pressure before and after the first dose if you have borderline hypertension. Contact your prescriber if nausea persists beyond 12 hours or if you notice any skin darkening on the face or gums (FDA prescribing information).